Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Do Elevated BNP Levels Predict Hemodynamically Significant PDAs

This study has been completed.
Sponsor:
Collaborator:
Alere, Inc.
Information provided by (Responsible Party):
Kate Tauber, Albany Medical College
ClinicalTrials.gov Identifier:
NCT01497054
First received: December 20, 2011
Last updated: July 2, 2013
Last verified: December 2011
  Purpose

The purpose of this study is to determine if B type natriuretic peptide (BNP) levels can be used to predict a hemodynamically significant patent ductus arteriosus (PDA). This peptide is produced by the ventricles in the heart when they are under stress, such as when a ductus remains open. If we can use a simple and inexpensive blood test to determine whether a PDA needs to be treated, we can potentially treat infants sooner than if they needed to wait for the availability of a cardiologist to perform an echocardiogram. This might decrease some of the deleterious effects of PDAs on the preterm infant such as bronchopulmonary dysplasia, necrotizing enterocolitis, renal hypoperfusion, and pulmonary hemorrhage. In a situation where follow up echocardiogram after a course of medical therapy shows persistent PDA, this test may help to decide whether this baby needs further treatment, either medical or surgical.


Condition
Patent Ductus Arteriosus

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diagnostic Prediction Value of B Type Natriuretic Peptide (BNP) Levels in Hemodynamically Significant Patent Ductus Arteriosus (hsPDA) in Premature Infants.

Resource links provided by NLM:


Further study details as provided by Albany Medical College:

Primary Outcome Measures:
  • BNP level and size of PDA [ Time Frame: within first 2 weeks of life ] [ Designated as safety issue: No ]
    BNP levels measured at several time points during first 2 weeks of life and compared to findings on echocardiogram to see if size of PDA correlated with BNP level.


Enrollment: 109
Study Start Date: December 2011
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Detailed Description:

B type natriuretic peptide (BNP) is mainly synthesized in the ventricles of the heart and released in response to volume and pressure loading and ventricular stress and, therefore, plays an important role in regulation of extracellular fluid volume. BNP causes diuresis, natriuresis, arterial and venous vasodilation and antagonizes the renin-angiotensin system resulting in a reduction in intravascular volume and decreased ventricular preload and afterload.

In adults, BNP levels have been routinely used to diagnose and measure the degree of congestive heart failure. In healthy term infants, BNP levels are initially elevated in the first few days of life but then decline over the ensuing week after birth to near adult levels by 3 months of age. However, in premature newborn infants there are still no normative values for BNP and, therefore, no agreed-upon cut off points to diagnose ventricular overload without confirmatory echocardiography. Patent ductus arteriosus (PDA) is the most common cause of ventricular overload and congestive heart failure in premature neonates and can be a cause of significant morbidity. Excessive pulmonary blood flow due to the aortopulmonary shunting can result in increased ventilatory dependency and thereby contribute to chronic lung disease. Other possible sequelae from a PDA include renal hypoperfusion, necrotizing entercolitis, and pulmonary hemorrhage. Early closure of a PDA has been shown to reduce these risks.

Delayed ductal closure is inversely related to GA at birth with the incidence varying from 20% in babies greater than 32 weeks gestation and up to 60% in babies less than 28 weeks gestation. Currently, infants are screened for a PDA by echocardiography. This requires that centers have access to cardiologists to perform and analyze these studies. A simple blood test that could help diagnose a hemodynamically significant PDA would be extremely helpful in low birth weight infants, especially in more remote centers that do not have routine access to cardiology services. To date, there is no accepted blood test although numerous studies are emerging suggesting that BNP might be such a test. It has been shown that the magnitude of shunting through a PDA is a major determinant of BNP level, however, the levels published in various studies for what is hemodynamically significant varies greatly. In addition, the studies that have been done previously are on small sample sizes (less than 70 patients, with one retrospective study that had 88 patients) and on various gestational ages and, therefore, it is difficult to extrapolate normative data.

It is already known that BNP levels are elevated in neonates with a hsPDA, however, there is little agreement on how high a BNP level needs to get to imply a hsPDA. We propose a study to measure the BNP values in all infants born less than 32 weeks gestation with and without a PDA. We will also do serial BNP levels with concurrent echocardiograms in infants with a PDA to determine a cutoff value of BNP above which an infant is likely to have a hsPDA. We hope that our study, with a larger sample size and on all infants with and without a PDA, will be able to not only gather more definitive data on what the cutoff BNP level is, but also gather normative BNP data on premature infants without PDAs.

  Eligibility

Ages Eligible for Study:   up to 24 Hours
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Preterm infants between 24 0/7 weeks gestation and 31 6/7 weeks gestation.

Criteria

Inclusion Criteria:

  • gestational age between 24 0/7 weeks gestation and 31 6/7 weeks gestation. - Infants must be enrolled by 24 hours of life.

Exclusion Criteria:

  • congenital heart disease,
  • necrotizing enterocolitis,
  • culture positive sepsis or culture negative but treated for presumed sepsis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01497054

Locations
United States, New York
Albany Medical Center Neonatal Intesive Care Unit
Albany, New York, United States, 12208
Sponsors and Collaborators
Albany Medical College
Alere, Inc.
Investigators
Principal Investigator: Kate A Tauber, MD Albany Medical College
Study Director: Upender K Munshi, MD Albany Medical College
Study Director: Robin Doyle, MD Capital Distric Pediatric Cardiology, affiliated with Albany Medical Center
  More Information

Publications:
Responsible Party: Kate Tauber, Principal Investigator, Albany Medical College
ClinicalTrials.gov Identifier: NCT01497054     History of Changes
Other Study ID Numbers: 3155
Study First Received: December 20, 2011
Last Updated: July 2, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Albany Medical College:
B type natriuretic peptide
Patent Ductus Arteriosus
Preterm infant

Additional relevant MeSH terms:
Ductus Arteriosus, Patent
Cardiovascular Abnormalities
Cardiovascular Diseases
Congenital Abnormalities
Heart Defects, Congenital
Heart Diseases
Natriuretic Peptide, Brain
Cardiovascular Agents
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014